Immunotherapy before standard treatment may boost survival in esophageal cancer
NCT ID NCT07306663
First seen Jan 08, 2026 · Last updated Apr 26, 2026 · Updated 20 times
Summary
This phase 3 trial tests whether adding immunotherapy (sintilimab) and chemotherapy before standard chemoradiotherapy helps people with inoperable esophageal cancer live longer and reduces the chance of the cancer coming back. About 242 adults aged 18-75 with stage II-IVA esophageal cancer will either receive the new combination or standard treatment alone. Researchers will track survival, side effects, and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.